Linden Capital Partners has acquired biomaterial-based medical products maker Collagen Matrix.
Collagen Matrix (CMI) is a developer and manufacturer of collagen-based and other mineral-based medical devices used for tissue and bone repair, and regeneration. The company’s products are sold on either a contract or private label basis to OEM customers that are active in the orthopedic, sports medicine, dental, and neurosurgery end markets.Collagen Matrix, founded in 1997, has more than 200 employees and is headquartered in Oakland, NJ (www.collagenmatrix.com).
“The CMI team’s unique understanding of collagen-based technologies along with their commitment to innovation and quality manufacturing make CMI stand out as a leading biomaterials developer and manufacturer,” said Gerard Moufflet, a Linden operating partner.
Linden is focused exclusively on leveraged buyouts in the healthcare and life science industries with a specific interest in medical products, specialty distribution, pharmaceutical, and services segments of healthcare. Linden’s strategy is based on three elements: healthcare and life science industry specialization; integrated private equity and operating expertise; and strategic relationships with large corporations.
“The CMI investment represents Linden’s subsector and operating partner-driven strategy, highlighting our ongoing focus on medical products, contract and private label manufacturing, and the dental and orthopedic sectors,” said Brian Miller, a managing partner of Linden.
In May 2018, Linden closed its fourth private equity fund, Linden Capital Partners IV LP, at the hard cap of $1.5 billion. Fund IV was oversubscribed and exceeded its target of $1.25 billion. The firm is based in Chicago (www.lindenllc.com).
© 2019 Private Equity Professional | August 2, 2019